Trial of nelipepimut S (NeuVax) in patients with gastric cancer in India

Trial Profile

Trial of nelipepimut S (NeuVax) in patients with gastric cancer in India

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Nelipepimut-S (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2017 According to a Sellas Life Sciences Group media release, SELLAS Life Science Group acquired Galena Biopharma, and subsequently Galena Biopharma changed its name to SELLAS Life Science Group.
    • 22 Jan 2014 New trial record
    • 14 Jan 2014 Galena Biopharma and Dr. Reddy's Laboratories have formed a strategic partnership for the development of nelipepimut S in India, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top